Regeneron COVID-19 antibody therapy available

Currently accepting treatment and prophylaxis orders at Salem Health COVID infusion clinic (formerly Parkside Clinic on 12th Street)

Emergency Use Authorizations for COVID-19 monoclonal antibody therapies have changed since Salem Health first started offering this treatment in December 2020, but antibody therapy with REGEN-COV (casirivimab+imdevimab) remains available at Parkside and we are working to increase capacity. 

REGEN-COV is now approved for subcutaneous administration, and the indication has expanded to include post-exposure prophylaxis in high risk individuals. IV and Sub-Q dosing is appropriate for both treatment and prophylaxis.  Parkside staff will triage patients to either IV or Sub-Q depending on staff availability and other factors. 

Treatment is for adult and pediatric patients who are:

• Within 10 days of onset of symptoms (ASAP is best)
• 12 years of age and older weighing at least 40 kg
• with positive results of direct SARS CoV-2 viral testing, AND
• at high risk for progression to severe COVID-19, including hospitalization or death.
• REGEN-COV treatment is NOT authorized for use in patients who are hospitalized or require oxygen due to COVID-19.

Prophylaxis is for adult and pediatric patients who are:

• 12 years of age and older weighing at least 40 kg
• at high risk for progression to severe COVID-19, including hospitalization or death, AND
• are not fully vaccinated, or not expected to mount an adequate immune response to vaccination, AND
• have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per CDC or are at high risk of exposure in an institutional setting such as a nursing home or prison

Salem Health is one of the few options around the state where this treatment is available. OHA and others are working rapidly to expand access in an effort to decrease hospitalizations and death due to COVID-19. In over 200 infusions of COVID-19 monoclonal antibody therapies, Salem Health has observed a 6% rate of admission to the hospital for worsening COVID symptoms versus a rate of 20% in eligible patients who declined treatment. This is a moderately larger difference than the early results from the casirivimab + imdevimab clinical trial, which showed 3% versus 9%, respectively.

Useful Links and information:

Epic Order No: CON1187

Infusion clinic phone number: 503-814-4638

REGEN-COV FAQ

REGEN-COV Provider Fact Sheet

REGEN-COV Patient Fact Sheet

REGEN-COV Emergency Use Authorization

REGEN-COV paper order sheets

If you have questions, please email Joshua Free.